Search Results

You are looking at 61 - 70 of 309 items for :

Clear All
Full access

Nicolas C. Issa and Lindsey R. Baden

-old man with multiple myeloma 10 months after allogeneic hematopoietic cell transplantation who presented with fevers, cough, headaches, and myalgia. He had received the trivalent influenza vaccine 1 month before admission (pandemic 2009 H1N1 vaccine was

Full access

Antonio Palumbo and Roberto Mina

Multiple myeloma is a malignant neoplasm accounting for 1% of all cancers and 10% of hematologic neoplasms. Its incidence increases with age: the median age at diagnosis is 70 years, with only 37% of patients younger than 65 years, 26% between the

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman and Matthew R. Smith

guidelines in oncology: multiple myeloma, v.2.2009 . Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf . Accessed May 21, 2009 . 8 Batson O . The role of vertebral veins in metastatic processes . Ann Intern Med

Full access

Luke Arney, Ryan Leib, Louise Schneider, Cori Kostick, Kerry Kilbridge, Ramin Khorasani, Oreofe Odejide and Lindsay C. Carter

treatment. For example, in a study of 3,831 older adults diagnosed with myeloma in the United States, the median time between the first myeloma-related symptom and diagnosis was 99 days (Friese CR, Leukemia & Lymphoma 2009). Such delays are associated with

Full access

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros and Arti Hurria

, and accumulating DNA damage. 8 These changes may underlie clinical differences in hematopoietic cell mobilization between older and younger patients. Older patients with myeloma tend to mobilize fewer total progenitor or CD34 + cells/kg, and require

Full access

Donald A. Podoloff, Douglas W. Ball, Edgar Ben-Josef, Al B. Benson III, Steven J. Cohen, R. Edward Coleman, Dominique Delbeke, Maria Ho, David H. Ilson, Gregory P. Kalemkerian, Richard J. Lee, Jay S. Loeffler, Homer A. Macapinlac, Robert J. Morgan Jr., Barry Alan Siegel, Seema Singhal, Douglas S. Tyler and Richard J. Wong

. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf . Accessed February 24, 2009 . 97 Schirrmeister H Bommer M Buck AK . Initial results in the assessment of multiple myeloma using 18F-FDG PET . Eur J Nucl Med Mol

Full access

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto and Tatsuo Akechi

VES-13 was no exception. 12 , 17 The incidence of hematologic cancer, especially malignant lymphoma and multiple myeloma, has been increasing in older patients. 18 , 19 The importance of CGA in these patients with cancer has been recognized, because

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

(CRC); bendamustine with or without rituximab (B±R) for non-Hodgkin's lymphoma (NHL); and lenalidomide with or without dexamethasone for multiple myeloma (MM). When this study was initiated, TC was established by the NCCN Myeloid Growth Factors

Full access

Stacey W. MucCullough, David Blaisdell, Jonathan K. Kish, Pat Farmer, JaLyna Laney, Tom Valuck, Natalie Dickson, Johnetta Blakely, Dianna Shipley, Jesus Berdeja, Gregg Shepard, Bertrand M. Anz III, Carolyn Kelsey, Jack Taylor, Chadi Nabhan, Jeffrey F. Patton and Annette Powers

Background: There is 1 multiple myeloma (MM) quality metric available (treatment with bisphosphonates, developed by the American Society of Hematology) to evaluate the quality of cancer care delivered to improve patient experience and outcomes. As

Full access

Raymond L. Comenzo

autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract] . Blood 2005 ; 106 : 230a . Abstract 780 . 43. Palumbo A Bertola A Musto P . Oral melphalan, prednisone, and thalidomide